Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases.

Akinrinmade OA, Chetty S, Daramola AK, Islam MU, Thepen T, Barth S.

Biomedicines. 2017 Sep 12;5(3). pii: E56. doi: 10.3390/biomedicines5030056. Review.

2.

Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.

Hristodorov D, Mladenov R, Huhn M, Barth S, Thepen T.

Toxins (Basel). 2012 Sep;4(9):676-94. doi: 10.3390/toxins4090676. Epub 2012 Sep 14. Review.

3.

Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.

Hristodorov D, Mladenov R, von Felbert V, Huhn M, Fischer R, Barth S, Thepen T.

MAbs. 2015;7(5):853-62. doi: 10.1080/19420862.2015.1066950.

4.

Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.

Hristodorov D, Mladenov R, Brehm H, Fischer R, Barth S, Thepen T.

MAbs. 2014;6(5):1283-9. doi: 10.4161/mabs.32182.

5.

Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.

Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S.

Br J Dermatol. 2010 Aug;163(2):279-86. doi: 10.1111/j.1365-2133.2010.09824.x. Epub 2010 Apr 26.

PMID:
20426788
6.

Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.

Hristodorov D, Mladenov R, Fischer R, Barth S, Thepen T.

Immunol Cell Biol. 2016 May;94(5):470-8. doi: 10.1038/icb.2016.4. Epub 2016 Jan 8.

PMID:
26743033
7.

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.

Mladenov R, Hristodorov D, Cremer C, Gresch G, Grieger E, Schenke L, Klose D, Amoury M, Woitok M, Jost E, Brümmendorf TH, Fendel R, Fischer R, Stein C, Thepen T, Barth S.

Oncotarget. 2016 Oct 11;7(41):67166-67174. doi: 10.18632/oncotarget.11568.

8.

Fcgamma receptor 1 (CD64), a target beyond cancer.

Thepen T, Huhn M, Melmer G, Tur MK, Barth S.

Curr Pharm Des. 2009;15(23):2712-8. Review.

PMID:
19689341
9.

Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin.

van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, Thepen T, van de Winkel JG.

Arthritis Rheum. 2003 May;48(5):1229-38.

10.

Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.

Schiffer S, Rosinke R, Jost E, Hehmann-Titt G, Huhn M, Melmer G, Barth S, Thepen T.

Int J Cancer. 2014 Sep 15;135(6):1497-508. doi: 10.1002/ijc.28786. Epub 2014 Mar 18.

11.

Resolution of cutaneous inflammation after local elimination of macrophages.

Thepen T, van Vuuren AJ, Kiekens RC, Damen CA, Vooijs WC, van De Winkel JG.

Nat Biotechnol. 2000 Jan;18(1):48-51.

PMID:
10625390
12.
14.

Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate.

van Roon JA, Bijlsma JW, van de Winkel JG, Lafeber FP.

Ann Rheum Dis. 2005 Jun;64(6):865-70. Epub 2004 Nov 11.

15.

Neutrophil CD64 expression in inflammatory autoimmune diseases: its value in distinguishing infection from disease flare.

Hussein OA, El-Toukhy MA, El-Rahman HS.

Immunol Invest. 2010;39(7):699-712. doi: 10.3109/08820139.2010.491520.

PMID:
20840056
16.

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y.

Pharmacol Ther. 2014 Feb;141(2):125-39. doi: 10.1016/j.pharmthera.2013.09.004. Epub 2013 Sep 27. Review.

PMID:
24076269
17.

Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells.

Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM.

J Immunol. 1996 Jul 15;157(2):541-8.

PMID:
8752900
18.

The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.

Mladenov R, Hristodorov D, Cremer C, Hein L, Kreutzer F, Stroisch T, Niesen J, Brehm H, Blume T, Brümmendorf TH, Jost E, Thepen T, Fischer R, Stockmeyer B, Barth S, Stein C.

Int J Cancer. 2015 Dec 1;137(11):2729-38. doi: 10.1002/ijc.29628. Epub 2015 Jun 12.

19.

Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application.

Moura CC, Segundo MA, Neves Jd, Reis S, Sarmento B.

Int J Nanomedicine. 2014 Oct 23;9:4911-22. doi: 10.2147/IJN.S68440. eCollection 2014.

20.

Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.

Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR.

PLoS One. 2012;7(8):e43361. doi: 10.1371/journal.pone.0043361. Epub 2012 Aug 24.

Supplemental Content

Support Center